Home » Topics » BioWorld Science

BioWorld Science
RSS

Neogene licenses portfolio of TCRs targeting KRAS and TP53 mutations from NCI

Jan. 12, 2022

G3PP is a therapeutic target for age-related metabolic diseases

Jan. 12, 2022

ABL and Sanofi enter collaboration and license agreement for ABL-301

Jan. 12, 2022

Dren Bio and Pfizer collaborate to discover and develop bispecific antibodies for cancer

Jan. 12, 2022

VCAM-1-targeting polyelectrolyte complex enhances therapeutic efficacy of miR-92a inhibitors in vivo

Jan. 12, 2022

PostEra and Pfizer expand strategic collaboration

Jan. 12, 2022

REVTx-99 demonstrates in vitro antiviral activity against SARS-CoV-2

Jan. 12, 2022

Methamphetamine harnessed for good in BBB transport

Jan. 12, 2022

CD6-ALCAM pathway is a therapeutic target in SLE

Jan. 12, 2022

Wigen Biomedicine Technology presents new CDK inhibitors

Jan. 12, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...